StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$43.11+0.12 (+0.28%)

Close on Nov 18, 2026Market cap $6.09BP/E –Yield –

Arrowhead Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Arrowhead Pharmaceuticals's pe ratio was 48.0× on Apr 30, 2026, against 87.1× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 202648.0×−382.7
2020Jul 31, 2020430.7×+338.8
2019Dec 31, 201991.9×–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?